These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12771490)

  • 1. Factor-XIIIa-positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyell's syndrome): paradoxical activation in skin and rarefaction in lymph nodes.
    Paquet P; Quatresooz P; Piérard GE
    Dermatology; 2003; 206(4):374-8. PubMed ID: 12771490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis.
    Paquet P; Paquet F; Al Saleh W; Reper P; Vanderkelen A; Piérard GE
    Am J Dermatopathol; 2000 Oct; 22(5):413-7. PubMed ID: 11048976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory function of factor-XIIIa-positive dendrocytes in incipient toxic epidermal necrolysis and graft-versus-host reaction. A hypothesis.
    Hermanns-Lê T; Paquet P; Piérard-Franchimont C; Arrese JE; Piérard GE
    Dermatology; 1999; 198(2):184-6. PubMed ID: 10325477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced toxic epidermal necrolysis and pancytopenia: a puzzling association.
    Paquet P; Jacob E; Pirson J; Pierard GE
    Int J Mol Med; 2005 Jul; 16(1):29-33. PubMed ID: 15942674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease.
    Deguchi M; Aiba S; Ohtani H; Nagura H; Tagami H
    Arch Dermatol Res; 2002 Oct; 294(7):297-302. PubMed ID: 12373334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal calprotectin in drug-induced toxic epidermal necrolysis.
    Paquet P; Piérard GE
    J Cutan Pathol; 1999 Jul; 26(6):301-5. PubMed ID: 10472759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythema multiforme and toxic epidermal necrolysis: a comparative study.
    Paquet P; Piérard GE
    Am J Dermatopathol; 1997 Apr; 19(2):127-32. PubMed ID: 9129696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased CD1a(+) , CD83(+) and factor XIIIa(+) dendritic cells in cervical lymph nodes and palatine tonsils of AIDS patients.
    Gondak R; Mauad T; Schultz L; Soares F; Kowalski LP; Vargas PA
    Histopathology; 2014 Jan; 64(2):234-41. PubMed ID: 24192235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological differential diagnosis of drug-induced toxic epidermal necrolysis (Lyell's syndrome) and acute graft-versus-host reaction.
    Paquet P; Arrese JE; Beguin Y; Piérard GE
    Curr Top Pathol; 2001; 94():49-63. PubMed ID: 11443887
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationship of factor XIIIa-positive dermal dendrocytes to Kaposi's sarcoma.
    Gray MH; Trimble CL; Zirn J; McNutt NS; Smoller BR; Varghese M
    Arch Pathol Lab Med; 1991 Aug; 115(8):791-6. PubMed ID: 1713758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome).
    Monteiro D; Egipto P; Barbosa J; Horta R; Amarante J; Silva P; Silva A
    Cutan Ocul Toxicol; 2017 Jun; 36(2):163-168. PubMed ID: 27487073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential pathomechanisms of epidermal necrolytic blistering diseases.
    Paquet P; Piérard GE
    Int J Mol Med; 2002 Dec; 10(6):695-9. PubMed ID: 12429994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vemurafenib-induced toxic epidermal necrolysis].
    Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
    Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4⁺ T cells.
    Yang C; Mosam A; Mankahla A; Dlova N; Saavedra A
    J Am Acad Dermatol; 2014 Jun; 70(6):1096-102. PubMed ID: 24629995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis.
    Paquet P; Jacob E; Damas P; Pirson J; Piérard G
    Arch Dermatol Res; 2005 Dec; 297(6):266-73. PubMed ID: 16249890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
    Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase of DC-LAMP+ mature dendritic cell subsets in dermatopathic lymphadenitis of mycosis fungoides.
    Tada K; Hamada T; Asagoe K; Umemura H; Mizuno-Ikeda K; Aoyama Y; Otsuka M; Yamasaki O; Iwatsuki K
    Eur J Dermatol; 2014; 24(6):670-5. PubMed ID: 25672788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.
    Cho YT; Lin JW; Chen YC; Chang CY; Hsiao CH; Chung WH; Chu CY
    J Am Acad Dermatol; 2014 Mar; 70(3):539-48. PubMed ID: 24388722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Stevens-Johnson Syndrom and Toxic Epidermal Necrolysis--based on literature].
    Łoboda J; Dudzik A; Chomyszyn-Gajewska M
    Przegl Lek; 2015; 72(1):35-7. PubMed ID: 26076576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome).
    Paquet P; Piérard GE; Quatresooz P
    Int Arch Allergy Immunol; 2005 Mar; 136(3):205-16. PubMed ID: 15713983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.